glp-1 heart failure reduced ejection fraction Frontiers Obesity and Heart Failure With

DNA methylation produces dynamic changes in the transcriptomes such as hypermethylation at CpG islands accounting for up to 60% of the promoter region and effectively inhibiting gene expression by maintaining heterochromatin status, whereas the non-coding regions are negatively correlated with DNA methylation (124)

Results from First Phase 2 Trial Describing a Triple Combination Regimen Targeting NASH Presented at The Liver Meeting Digital Experience

Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability

But its important to point out that the labor market is also showing increasing signs of weakness